Nogo receptor antagonists and methods of increasing neurite outgrowth

Patent metadata

Field	Value
Publication number	US-9228015-B2
Application number	US-201414146345-A
Country	US
Kind code	B2
Filing date	Jan 2, 2014
Priority date	Jan 27, 2006
Publication date	Jan 5, 2016
Grant date	Jan 5, 2016

Abstract

Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

First claim

It is claimed that:

1. A method of treating a central nervous system (CNS) disease, disorder, or injury in a mammal selected from the group comprising stroke, spinal cord injury, optic neuritis, and glaucoma, comprising administering to a mammal in need of treatment an effective amount of an agent comprising a NogoR polypeptide variant comprising:
a sNogoR310 polypeptide, comprising the amino acid sequence of residues 27-310 of SEQ ID NO: 58; and
an antibody fragment, crystallizable (Fc):
wherein the Fc is joined to the sNogoR310 c-terminus,
wherein the NogoR variant inhibits neurite outgrowth inhibition.

2. The method of claim 1 wherein the subject receives a NogoR polypeptide variant in combination with another therapy.

3. The method of claim 1 , wherein the agent comprises a dimeric peptide comprising two of the NogoR variants.

4. A method of enhancing neurite outgrowth comprising administering to a mammal in need of treatment an effective amount of an agent comprising a NogoR polypeptide variant comprising:
a sNogoR310 polypeptide, comprising the amino acid sequence of residues 27-310 of SEQ ID NO: 58: and
an antibody fragment, crystallizable (Fc);
wherein the Fc is joined to the sNogoR310 c-terminus,
wherein the NogoR variant inhibits neurite outgrowth inhibition.

5. The method of claim 1 , wherein the CNS disease, disorder, or injury is a spinal cord injury.

Assignees

• Biogen Idec Inc

Inventors

• Lee Daniel H S
• Wen Dingyi
• Pepinsky R Blake
• Relton Jane K
• Wang Xinzhong
• Lugovskoy Alexey
• Meier Werner
• Garber Ellen A
• Silvian Laura
• Weinreb Paul H

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P5/38

  of the suprarenal hormones · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title